Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 07th of April, we plan to work on 21 projects. Review the complete list of planned activities in this post.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Tanner et al. examined key cross-functional challenges stemming from Joint Scientific Consultations (JSC) and Joint Clinical Assessments (JCA) and how manufacturers should address them in their EU HTAR readiness plans. Conducted through literature review, guidance analysis, and manufacturer insights, the study identified five key cross-functional areas: global asset strategy, non-EU regional readiness, launch sequence evolution, brand perception, and pricing impacts. Given the central role of market access in bringing innovation to patients, the EU HTAR will have far-reaching implications, with early Joint Clinical Assessment reports expected to significantly influence brand strategy, pricing dynamics, and global launch sequencing.

The Danish Health Data Authority quarterly updates the Health Care Classification System (SKS). The latest version was published in mid-March 2025 to come into force on April 1, 2025. Among other changes, fifty-one new procedure codes were introduced concerning cardiovascular, diagnostic imaging, dermatology, gastrointestinal, nephrology and urology, nuclear medicine, orthopedics, peripheral vascular, pulmonary and airways, surgical procedures, robotic surgery, and some other fields.

MTRC is pleased to announce the release of its latest White Paper: "Challenges of Health Economic Evaluations of In-Vitro Diagnostic Tests". This white paper examines the unique challenges involved in conducting health economic evaluations of IVD tests and outlines practical best practices.

On March 19, 2025, the NHS Innovation Accelerator (NIA) announced 28 new innovators (“Fellows”) with healthcare solutions awarded to join the program in 2025. NIA provides intensive, tailored support to proven healthcare solutions, helping to accelerate their adoption and maximize their impact across the NHS. Awarded innovations concern e-Health, in-vitro diagnostic, gynecology, neuromodulation, and sustainability.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Ali et al. explored practical strategies to reduce the carbon footprint of dermatological surgery in the UK, aligning with the National Health Service's commitment to sustainability. The review outlined systemic measures such as sourcing from local suppliers to cut transport-related emissions, implementing streamlined care pathways, and promoting responsible prescribing. It also emphasized the integration of environmental principles into surgical education and the optimization of resource use for consumables, equipment, and energy.

On March 23, 2025, the Norwegian Directorate of Health released an updated version of the Norwegian Laboratory Code (NLK) system and associated tariffs to be implemented no later than May 1, 2025. A total of 143 new codes were added in the biochemistry, microbiology, clinical pharmacology, and immunology fields

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Mascarenhas et al. analyzed the landscape of economic evaluations for medical devices in pediatrics, critically appraising their methodological rigor. The systematic literature review identified 39 economic evaluations, with a focus on high-risk therapeutic devices mostly studied in high-income countries. The analysis showed a predominant use of cost-utility analysis and considerable variation in adherence to CHEERS 2022 reporting standards. The findings highlight the need to improve reporting quality and develop methods that reflect the unique health needs of children, including outcome measures meaningful to pediatric patients and their families.

In March 2025, the French government announced a €3.9 billion increase in funding for healthcare establishments, raising the total hospital budget to €109.6 billion, a 3.8% increase from the previous year.

In March 2025, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedures Guidance on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Cucherat et al. proposed formalized methodological criteria for observational studies to serve as credible evidence for health product effectiveness, comparable to randomized controlled trials. Developed through a French expert roundtable, the framework emphasizes predefined protocols and statistical analysis plans, robust causal inference, and minimization of bias. The results offer a structured approach to support regulatory decisions and guideline development.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Lipska et al. explored the policy challenges surrounding the implementation of the EU HTA Regulation, drawing from the discussions of a high-level expert group convened in Rome. The authors proposed actionable recommendations to facilitate the effective launch of the Joint Clinical Assessment framework. Their key insights stress the need for transparent communication, stakeholder engagement, and equitable commitment from all member states to reduce access delays across Europe.